Suntrust Banks’s Alterity Therapeutics ATHE Stock Holding History

Suntrust Banks’s Portfolio ATHE Stock Details ATHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-200	Closed	-$25K	–	1177
2014 Q3	$25K	Hold	200	–	–	﹤0.01%	1369
2014 Q2	$27K	Hold	200	–	–	﹤0.01%	1397
2014 Q1	$33K	Hold	200	–	–	﹤0.01%	1886
2013 Q4	$84K	Hold	200	–	–	﹤0.01%	1790
2013 Q3	$49K	Buy	+200	New	+$45.9K	﹤0.01%	1790

Other funds holding ATHE

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

GBA

Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

CAM

Columbia Asset Management Ann Arbor, Michigan $575M AUM 29.81% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Suntrust Banks's ATHE Position: Q4 2014 in Review

Suntrust Banks sold out of Alterity Therapeutics (ATHE) in Q4 2014, closing a stake of 200 shares — an estimated $25K sold.

Suntrust Banks first reported a position in ATHE in Q3 2013 and held it in 5 quarters. The position peaked at $84K in Q4 2013. 24 funds tracked by Wall St. Rank hold ATHE as of Q4 2014.

Suntrust Banks reported no remaining Alterity Therapeutics position as of Q4 2014 after selling out during the quarter.
Suntrust Banks sold 200 Alterity Therapeutics shares in Q4 2014, an estimated $25K.
Suntrust Banks first reported a position in Alterity Therapeutics in Q3 2013 and held it in 5 quarters.
Suntrust Banks's Alterity Therapeutics position peaked at $84K in Q4 2013.
24 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q4 2014.

Based on Suntrust Banks's 13F filing for Q4 2014, filed 12 Feb 2015.